IK6 isoform with associated cytogenetic and molecular abnormalities in Chinese patients with Philadelphia chromosome-positive adult acute lymphoblastic leukemia

References

• Talamo A, Chalandonb Y, Marazzi Y, et al. Clonal heterogeneity and chromosomal instability at disease presentation in high hyperdiploid acute lymphoblastic leukemia. Cancer Genet Cytogenet 2010;203:209–214.
   Google Scholar
• Mancini M, Scapaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005;105:3434–3441.
   PubMed Web of Science ®Google Scholar
• Rieder H, Ludwig WD, Gassmann W, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996;95:678–691.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99:1860–1862.
   PubMed Web of Science ®Google Scholar
• Nera KP, Alinikula J, Terho P, et al. Ikaros has a crucial role in regulation of B cell receptor signaling. Eur J Immunol 2006;36:516–525.
   PubMed Web of Science ®Google Scholar
• Merkenschlager M. Ikaros in immune receptor signaling, lymphocyte differentiation, and function. FEBS Lett 2010;584: 4910–4914.
   PubMed Web of Science ®Google Scholar
• Ramirez J, Lukin K, Hagman J. From hematopoietic progenitors to B cells:mechanisms of lineage restriction and commitment. Curr Opin Immunol 2010;22:177–184.
   PubMed Web of Science ®Google Scholar
• Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994;79:143–156.
   PubMed Web of Science ®Google Scholar
• Meleshko AN, Movchan LV, Belevtsev MV, et al. Relative expression of different ikaros isoforms in childhood acute leukemia. Blood Cells Mol Dis 2008;41:278–283.
   PubMed Web of Science ®Google Scholar
• Molnar A, Georgopoulos K. The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins. Mol Cell Biol 1994;14:8292–8303.
   PubMed Web of Science ®Google Scholar
• Tonnelle C, Dijon M, Moreau T, et al. Stage specific over-expression of the dominant negative ikaros 6 reveals distinct role of ikaros throughout human B-cell differentiation. Mol Immunol 2009;46:1736–1743.
   PubMed Web of Science ®Google Scholar
• Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 2010; 24:1200–1224.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;29:470–480.
   Web of Science ®Google Scholar
• Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125–134.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110–114.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Cilloni D, et al. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica 2008;93:1814–1821.
   PubMed Web of Science ®Google Scholar
• Cross NCP. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355–365.
   PubMed Web of Science ®Google Scholar
• The Group Francais de Cytogenetique Hematologigue. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A collaborative study of the Group Français de Cytogénétique Hématologique. Blood 1996;67:3135–3142.
   Google Scholar
• Yeoh E-J, Ross ME, Shurtieff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133–143.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alteration in acute lymphoblastic leukemia. Nature 2007; 446:758–764.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008;112:3847–3855.
   PubMed Web of Science ®Google Scholar
• Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010;24:1258–1264.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterisation of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukaemia patients: on behalf of GIMEMA AL WP. Blood 2009;114: 2159–2167.
   PubMed Web of Science ®Google Scholar
• Heerema NA, Harbott J, Galimberti S, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 2004;18:693–702.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Dodge RK, Mrozok K, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 2004;124:275–288.
   PubMed Web of Science ®Google Scholar
• Yahada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24:460–466.
   PubMed Web of Science ®Google Scholar
• Zhuang Z, Jones D, Yao H, et al. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol 2010;23:1524–1534.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009;27:5202–5207.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2007;110:727–734.
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008;113:985–994.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99:1860–1862.
   PubMed Web of Science ®Google Scholar
• Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168–2171.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322:1377–1380.
   PubMed Web of Science ®Google Scholar